Physician profile
Ku-In Kang
NPI 1902267461
$7,331.35
in general payments reported to CMS, 2019-2025
35 companies · $1,830 in 2025
The $1,830 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,998 · 2023: $1,604 · 2024: $1,900 · 2025: $1,830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,273 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,272.75 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,114.36 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $704.89 | 2022-2025 | |
| Amgen INC. | $630.44 | 2022-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals Lp | $623.04 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $421.05 | 2022-2025 | Ozempic, Rybelsus |
| Gilead Sciences, INC. | $408.25 | 2022-2025 | Vemlidy |
| Sumitomo Pharma America, INC. | $371.91 | 2024-2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $299.55 | 2022-2023 | |
| Astellas Pharma US INC | $293.59 | 2023-2025 | Veozah |
| Scilex Pharmaceuticals INC. | $270.32 | 2022-2025 | Ztlido |
| Aimmune Therapeutics, INC. | $265.29 | 2024-2025 | Zenpep |
| Lilly USA, LLC | $248.04 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Ardelyx, INC. | $223.65 | 2023-2025 | Ibsrela |
| Ibsa Pharma INC. | $170.74 | 2023-2024 | Licart, Tirosint, Tirosint |
| Amarin Pharma, INC. | $155.02 | 2022-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $152.32 | 2023-2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $147.75 | 2025 | Ams 700, General - Pain Management |
| Pfizer INC. | $134.09 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $114.26 | 2022-2023 | |
| Dexcom, INC. | $81.82 | 2022-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $75.65 | 2023-2024 | Korlym |
| Xeris Pharmaceuticals, INC. | $64.53 | 2023-2025 | Gvoke Hypopen, Keveyis |
| Kowa Pharmaceuticals America, INC. | $58.42 | 2022-2024 | Zoryve |
| Azurity Pharmaceuticals, INC. | $57.25 | 2023-2025 | Horizant, Edarbi, Horizant |
| Merck Sharp & Dohme LLC | $33.94 | 2023-2025 | Dificid, Capvaxive, Gardasil 9 |
| Radius Health, INC. | $30.71 | 2024 | Tymlos |
| Vivus LLC | $26.50 | 2025 | Pancreaze |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.64 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.90 | 2025 | Xifaxan |
| Invivyd INC | $21.15 | 2025 | Pemgarda |
| Averitas Pharma INC. | $19.24 | 2024 | Qutenza |
| Esperion Therapeutics, INC. | $16.77 | 2024 | Nexletol |
| Glaxosmithkline, LLC. | $16.37 | 2023 | Shingrix |
| Corium, LLC | $15.90 | 2023 | Adlarity |
| Eisai INC. | $15.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ku-In Kang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.